C3.ai Inc vs Medpace Holdings Inc — how do they compare? C3.ai Inc trades at $10.11 (market cap $1.65B), while Medpace Holdings Inc trades at $597.39 (market cap $16.90B). The key difference: Medpace Holdings Inc is far larger — about 10.2× C3.ai Inc's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, C3.ai Inc nearer its low. Which is the better fit depends on your goals.
| AI | MEDP | |
|---|---|---|
Market Cap | $1.65B | $16.90B |
Sector | Technology | Technology |
52-Week High | $19.66 | $620.59 |
52-Week Low | $7.76 | $393.42 |
Enterprise Value | $1.08B | $16.52B |
Signals from Pluang's Aura AI — not financial advice
C3.ai (AI) trades at $10.125, down 2.64% on the day, with a bullish technical signal from moving averages despite overbought RSI readings. The company reported revenue of $389.06 million in 2025 but a net loss of $288.70 million, reflecting persistent unprofitability. Recent news highlights C3.ai being named a leader in AI platforms by Forrester Research (Business Wire, August 10, 2026), though CFO share sales and mixed earnings beats add complexity.
The stock faces significant fundamental challenges with negative margins and cash flow, but analyst consensus is mixed with a $10.20 price target near current levels. Investment opportunity hinges on AI platform adoption growth, while risks include sustained losses, competitive pressure, and high valuation multiples absent earnings.
MEDP trades at $600.00, down 0.4% on the day, with a bullish technical signal driven by moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $4.25, and raised full-year guidance. Revenue growth is robust, with 2026 projected at $2.8 billion, though valuation multiples like a P/E of 35.58 and P/B of 38.95 are elevated. Net cash flow is expected to turn positive in 2026, and institutional activity is mixed, with some funds increasing stakes while others trim positions.
Outlook is positive due to earnings momentum and record bookings, but risks include high valuation sensitivity and a shareholder lawsuit investigation. Analyst consensus is a $599.57 price target with a 'Hold' bias, suggesting limited near-term upside from current levels amid growth-priced expectations.
Trailing returns across standard periods
Latest headlines on both assets
C3.ai Inc is an enterprise artificial intelligence company. The company provides software-as-a-service applications that enable customers to rapidly develop, deploy, and operate large-scale Enterprise AI applications across any infrastructure. It provides solutions under three divisions namely, The C3 AI Suite, is a comprehensive application development and runtime environment that is designed to allow customers to rapidly design, develop, and deploy Enterprise AI applications of any type
Read more on AI →Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →